After Quad summit, US to finance India's coronavirus vaccine manufacturer

United States has announced to finance India's coronavirus vaccine manufacturer after a mega initiative was taken by the Quad leaders for India to produce vaccines for Indo-Pacific region.

The U.S. International Development Finance Corporation (DFC) has announced it will work with Indian manufacturer Biological E to finance increased capacity to support the firm's effort to produce at least 1 billion doses of Covid-19 vaccines by the end of 2022. United in our fight against COVID-19, we launched a landmark Quad partnership to ensure accessibility of safe COVID-19 vaccines. India’s formidable vaccine production capacity will be expanded with support from Japan, US & Australia to assist countries in the Indo-Pacific region. The support will be with Stringent Regulatory Authorization (SRA) and/or World Health Organization (WHO) Emergency Use Listing (EUL). The announcement is part of the agency’s Global Health and Prosperity Initiative, under which the agency is working to increase manufacturing, production and distribution capacity for vaccines, including the Covid-19 vaccine.